Ahmed A H Abdellatif1,2,3, Robert Hennig4, Klaus Pollinger4, Hesham M Tawfeek5, Abdellatif Bouazzaoui6,7, Achim Goepferich4. 1. Department of Pharmaceutics, College of Pharmacy, Qassim University, Buraydah, 51452, Qassim, Kingdom of Saudi Arabia. a.abdellatif@qu.edu.sa. 2. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Assiut, 71524, Egypt. a.abdellatif@qu.edu.sa. 3. Department of Pharmaceutical Technology Department, Faculty of Chemistry and Pharmacy, Regensburg University, 93040, Regensburg, Germany. a.abdellatif@qu.edu.sa. 4. Department of Pharmaceutical Technology Department, Faculty of Chemistry and Pharmacy, Regensburg University, 93040, Regensburg, Germany. 5. Department of Industrial Pharmacy, Faculty of Pharmacy, Assiut University, 71526 Assiut, Egypt. 6. Department of Medical Genetics, Faculty of Medicine, Umm Al-Qura University, P.O. Box 715, Makkah, 21955, Saudi Arabia. 7. Science and Technology Unit, Umm Al Qura University, P.O. Box 715, Makkah, 21955, Saudi Arabia.
Abstract
BACKGROUND: Leukaemia is the most prevalent form of cancer-causing death in a large number of populations and needs prompt and effective treatment. Chemotherapeutics can be used to treat leukaemia, but their pronounced killing effects to other living cells is still an issue. Active targeting to certain specific receptors in leukaemic cells is the best way to avoid damage to other living cells. Leukaemic cells can be targeted using novel nanoparticles (NPs) coated with a specific ligand, such as octreotide (OCD), to target somatostatin receptor type 2 (SSTR2), which is expressed in leukaemic cells. METHODS: Amino-PEGylated quantum dots (QDs) were chosen as model NPs. The QDs were first succinylated using succinic anhydride and then coated with OCD. The reactivity and selectivity of the formulated QDs-OCD were studied in cell lines with well-expressed SSTR2, while fluorescence was detected using confocal laser scanning microscopy (CLSM) and flow cytometry (FACS). Conclusively, QD-OCD targeting to blood cells was studied in vivo in mice and detected using inductively coupled plasma mass spectrometry and CLSM in tissues. RESULTS: Highly stable QDs coated with OCD were prepared. FACS and CLSM showed highly definite interactions with overexpressed SSTR2 in the investigated cell lines. Moreover, the in vivo results revealed a higher concentration of QDs-OCD in blood cells. The fluorescence intensity of the QDs-OCD was highly accumulated in blood cells, while the unmodified QDs did not accumulate significantly in blood cells. CONCLUSION: The formulated novel QDs-OCD can target SSTR2 overexpressed in blood cells with great potential for treating blood cancer.
BACKGROUND:Leukaemia is the most prevalent form of cancer-causing death in a large number of populations and needs prompt and effective treatment. Chemotherapeutics can be used to treat leukaemia, but their pronounced killing effects to other living cells is still an issue. Active targeting to certain specific receptors in leukaemic cells is the best way to avoid damage to other living cells. Leukaemic cells can be targeted using novel nanoparticles (NPs) coated with a specific ligand, such as octreotide (OCD), to target somatostatin receptor type 2 (SSTR2), which is expressed in leukaemic cells. METHODS: Amino-PEGylated quantum dots (QDs) were chosen as model NPs. The QDs were first succinylated using succinic anhydride and then coated with OCD. The reactivity and selectivity of the formulated QDs-OCD were studied in cell lines with well-expressed SSTR2, while fluorescence was detected using confocal laser scanning microscopy (CLSM) and flow cytometry (FACS). Conclusively, QD-OCD targeting to blood cells was studied in vivo in mice and detected using inductively coupled plasma mass spectrometry and CLSM in tissues. RESULTS: Highly stable QDs coated with OCD were prepared. FACS and CLSM showed highly definite interactions with overexpressed SSTR2 in the investigated cell lines. Moreover, the in vivo results revealed a higher concentration of QDs-OCD in blood cells. The fluorescence intensity of the QDs-OCD was highly accumulated in blood cells, while the unmodified QDs did not accumulate significantly in blood cells. CONCLUSION: The formulated novel QDs-OCD can target SSTR2 overexpressed in blood cells with great potential for treating blood cancer.
Authors: Ahmed A H Abdellatif; Ahmed Abdelfattah; Abdellatif Bouazzaoui; Shaaban K Osman; Issa Saad Al-Moraya; Abdulaziz M Saleh Showail; Mansour Alsharidah; Ashraf Aboelela; Osamah Al Rugaie; Tarek M Faris; Hesham M Tawfeek Journal: Bioinorg Chem Appl Date: 2022-09-30 Impact factor: 4.724